[EN] CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS [FR] CONJUGUÉS COMPRENANT DES AGENTS DE LIAISON CELLULAIRE (CBA) ET DES AGENTS CYTOTOXIQUES
[EN] CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS [FR] CONJUGUÉS COMPRENANT DES AGENTS DE LIAISON CELLULAIRE ET DES AGENTS CYTOTOXIQUES
Conjugates comprising cell-binding agents and cytotoxic agents
申请人:ImmunoGen, Inc.
公开号:US10988531B2
公开(公告)日:2021-04-27
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS
申请人:ImmunoGen, Inc.
公开号:EP3188733B1
公开(公告)日:2019-11-06
CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS
申请人:IMMUNOGEN, INC.
公开号:US20150359903A1
公开(公告)日:2015-12-17
The invention provides linker compounds containing a disulfide group, and maytansin-derived cytotoxic compounds that are useful for forming a CBA-drug conjugates, and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.
US9999680B2
申请人:——
公开号:US9999680B2
公开(公告)日:2018-06-19
[EN] CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS<br/>[FR] CONJUGUÉS COMPRENANT DES AGENTS DE LIAISON CELLULAIRE (CBA) ET DES AGENTS CYTOTOXIQUES
申请人:IMMUNOGEN INC
公开号:WO2014134483A2
公开(公告)日:2014-09-04
The invention provides linker compounds and cytotoxic compounds that are useful for forming a CBA-drug conjugates, and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.